semaglutide approved for obesity 50 mg of oral #semaglutide daily was associated with body weight reduction and improved cardiometabolic risk factors in East Asian adults with overweight or #obesity, with or without type 2 #diabetes. https://ja.ma/41sPiYj Weight-loss drug given green light

However, because the control beverage elicited similar lipid-lowering effects in hypercholesterolemic participants, and due to the short study duration and small sample size, further research is needed to clarify yerba mates long-term efficacy, optimal dosing, and potential role in populations with chronic conditions such as type 2 diabetes, obesity, or advanced cardiovascular disease

Cardiovascular Protection: GLP-1s are proven to lower blood pressure and improve cholesterol levels

Two Phase 2 trials were conducted concurrently: one in adults with obesity without diabetes, published in the New England Journal of Medicine in June 2023, and one in adults with type 2 diabetes, published simultaneously in The Lancet

A thoughtful needs analysis can help pharmacies avoid costly purchasing errors while improving product quality, workflow efficiency, and employee safety